{"id": "367952", "url": "https://fevir.net/resources/Evidence/367952", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"], "versionId": "26", "lastUpdated": "2025-08-18T13:22:42.074Z"}, "name": "NCT03640312_otherOutcomeMeasure_0_OutcomeAnalysis_11_BetweenGroupAnalysis_OG000_OG001", "title": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367952. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367952. Computable resource at: https://fevir.net/resources/Evidence/367952#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "statistic": [{"note": [{"text": "Outcome Analysis NonInferiority Type: Superiority"}], "quantity": {"unit": "Participants", "value": -0.06}, "statisticType": {"text": "Risk Difference (RD)"}, "attributeEstimate": [{"type": {"coding": [{"code": "STATO:0000037", "system": "https://fevir.net/sevco", "display": "standard error of the mean"}]}, "quantity": {"unit": "Participants", "value": 0.04}}, {"type": {"coding": [{"code": "C44185", "system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type", "display": "P-value"}]}, "quantity": {"value": 0.49}}, {"note": [{"text": "CI Number of Sides: 2-Sided"}], "type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type", "code": "C53324", "display": "Confidence interval"}]}, "level": 0.95, "range": {"low": {"unit": "Participants", "value": -0.15}, "high": {"unit": "Participants", "value": 0.02}}}], "modelCharacteristic": [{"code": {"text": "Fisher Exact"}}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "367952", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-0-OutcomeAnalysis-11-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Evidence", "variableDefinition": [{"note": [{"text": "All randomized participants"}], "intended": {"type": "Group", "reference": "Group/367881", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312 Eligibility Criteria", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "population"}, {"observed": {"display": "Group Assignment: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. vs. Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}, "description": "Group Assignment: QUARTET LDQT vs. Candesartan", "variableRole": "exposure", "comparatorCategory": "Candesartan"}, {"observed": {"type": "EvidenceVariable", "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367896", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "outcome"}], "description": "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide."}